grant
University of Pennsylvania Patient-derived Xenograft Development and Trials Center
Organization UNIVERSITY OF PENNSYLVANIALocation PHILADELPHIA, UNITED STATESPosted 5 Jul 2023Deadline 30 Jun 2028
NIHUS FederalResearch GrantFY202515 year old15 years of ageAML - Acute Myeloid LeukemiaAcute Myeloblastic LeukemiaAcute Myelocytic LeukemiaAcute Myelogenous LeukemiaAntioncogene Protein p53Bioinformatics coreBioinformatics research coreBioinformatics resource coreBiologyBreast CancerCancer cell lineCancersCellular Tumor Antigen P53Center for Cancer ResearchCharacteristicsClear cell renal cell carcinomaClinicalClinical TrialsCollectionCombined Modality TherapyCommunitiesCore FacilityDedicationsDevelopmentDiseaseDisorderEarly-Stage Clinical TrialsGlioblastomaGoalsGrade IV Astrocytic NeoplasmGrade IV Astrocytic TumorGrade IV AstrocytomaHDM2HepatocarcinomaHepatocellular CarcinomaHepatocellular cancerHepatomaHeterograftHeterologous TransplantationHistoryHumanHuman ResourcesInfectionInfection ControlInvestigatorsLinkLiver Cells CarcinomaMDM2MDM2 geneMDMX proteinMalignantMalignant - descriptorMalignant Breast NeoplasmMalignant NeoplasmsMalignant Ovarian NeoplasmMalignant Ovarian TumorMalignant TumorMalignant Tumor of the OvaryMalignant neoplasm of ovaryManpowerMdm-2 proteinMeasuresMeninMiceMice MammalsModelingModern ManMolecularMultimodal TherapyMultimodal TreatmentMultiple MyelomaMurineMusNCI Center for Cancer ResearchNon-MalignantOncoprotein MDM2Oncoprotein p53OvarianOvarian Clear Cell CancerOvarian Clear Cell CarcinomaOvarian Clear Cell NeoplasmOvarian Clear Cell TumorOvarian Serous AdenocarcinomaOvarian Serous CarcinomaOvary CancerP53PDX modelPatient derived xenograftPatientsPennsylvaniaPhasePhase 1 Clinical TrialsPhase 1/2 Clinical TrialPhase I Clinical TrialsPhase I/II Clinical TrialPhosphoprotein P53Phosphoprotein pp53Pilot ProjectsPlasma-Cell MyelomaPrimary carcinoma of the liver cellsProgenitor CellsProtein TP53Recording of previous eventsReproducibilityResearchResearch PersonnelResearchersSamplingSerous Adenocarcinoma of the OvarySerous Carcinoma of the OvaryTP53TP53 geneTRP53TestingTherapeuticTissue BanksTissue CollectionTissue repositoryTumor Protein p53Tumor Protein p53 GeneUniversitiesUniversity resourcesWorkXenograftXenograft ModelXenograft procedureXenotransplantationacute granulocytic leukemiaacute myeloid leukemiaage 15 yearsanimal facilitybio-informatics infrastructurebioinformatics infrastructureburden of diseaseburden of illnesscancer typecancers that are rareccRCCclinical implementationcombination therapycombined modality treatmentcombined treatmentdevelopmentaldisease burdenexperiencefifteen year oldfifteen years of ageglioblastoma multiformehistoriesindividualized cancer careindividualized oncologyliver carcinomamalignancymalignant breast tumormdm-2 oncogene proteinmdm2 proteinmembermortalitymulti-modal therapymulti-modal treatmentmyelomamyelomatosisneoplasm/cancernew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapeuticsnew therapynew therapy approachesnew treatment approachnew treatment strategynext generation therapeuticsnonmalignantnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapeuticsnovel therapynovel therapy approachovarian cancerp53 Antigenp53 Genesp53 Tumor Suppressorp53-Binding Protein MDM2patient derived xenograft modelpersonalized oncologypersonnelphase 2 studyphase I protocolphase II studypilot studypre-clinicalprecision cancer careprecision cancer medicineprecision oncologypreclinicalprotein p53rare cancerrare malignancyrare tumorresponseresponse to therapyresponse to treatmentskillsspongioblastoma multiformestem cellstargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic responsetherapy responsetranslational opportunitiestranslational potentialtreatment responsetreatment responsivenesstumorxeno-transplantxeno-transplantationxenograft transplant modelxenotransplant model
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
or
— or —Get email alerts for similar roles
Description preview
Project Summary/Abstract:
The overall goal of the University of Pennsylvania PDX Development and Therapeutics Center (UP-PDTC) is
to (i) exploit the translational potential of PDX models for evaluating the response of various treatments in
models with specific molecular characteristics and to (ii) work with PDXNet to enhance and extend use of PDX…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click